OTCMKTS:BIXT Bioxytran (BIXT) Stock Price, News & Analysis $0.03 0.00 (-9.84%) As of 12:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsBuy This Stock About Bioxytran Stock (OTCMKTS:BIXT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bioxytran alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0452-Week Range$0.03▼$0.11Volume10,666 shsAverage Volume247,503 shsMarket Capitalization$3.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bioxytran, Inc. is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings. Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release. These formulations are engineered to minimize oxidative stress and inflammation while enhancing tissue recovery. The company maintains a patent portfolio covering key geographies, including North America, Europe, and Asia, and is actively exploring collaborative partnerships to support development and potential global commercialization. Originating from foundational work in synthetic oxygen therapeutics, Bioxytran has transitioned from early-stage research into a specialized biopharmaceutical developer. The management team brings together expertise in biotechnology R&D, regulatory strategy, and manufacturing scale-up. Bioxytran continues to pursue strategic alliances and funding initiatives to advance its mission of delivering innovative oxygen-based therapies that improve patient outcomes in critical therapeutic areas.AI Generated. May Contain Errors. Read More Receive BIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIXT Stock News HeadlinesBioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25May 29, 2026 | globenewswire.comBioxytran Delays Annual 10-K FilingApril 1, 2026 | tipranks.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.June 26 at 1:00 AM | Behind the Markets (Ad)Bioxytran Raises Capital to Advance Development and CommercializationMarch 20, 2026 | tipranks.comBIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENTMarch 20, 2026 | globenewswire.comBioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-MMarch 4, 2026 | globenewswire.comBioxytran Reports Positive ProLectin-M Phase 1b/2a COVID TrialMarch 2, 2026 | tipranks.comBioxytran, Inc.: Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu VirusFebruary 23, 2026 | finanznachrichten.deSee More Headlines BIXT Stock Analysis - Frequently Asked Questions How have BIXT shares performed this year? Bioxytran's stock was trading at $0.0753 at the beginning of 2026. Since then, BIXT stock has decreased by 62.3% and is now trading at $0.0284. How were Bioxytran's earnings last quarter? Bioxytran, Inc. (OTCMKTS:BIXT) posted its quarterly earnings data on Friday, May, 15th. The company reported ($0.02) earnings per share for the quarter. How do I buy shares of Bioxytran? Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioxytran own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX). Company Calendar Last Earnings5/15/2026Today6/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BIXT CIK1445815 Webwww.bioxytraninc.com Phone(617) 454-1199FaxN/AEmployees2Year Founded2008Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.12 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-737.48% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-1.42Miscellaneous Outstanding Shares114,690,000Free Float34,409,000Market Cap$3.26 million OptionableNot Optionable Beta1.69 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:BIXT) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredGold Will Hit $4,900JPMorgan now sees gold hitting $4,900, and central banks are buying at a record 710 tonnes per quarter. Trump'...Investors Alley | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredNNVC Scores Big FDA Measles WinNanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387 as a measles treatment, unlock...Equiscreen | SponsoredNew "AI Fuel" discovered near Grand CanyonA drilling crew near the Grand Canyon just uncovered an energy source the International Energy Agency says is ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
